Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

Tanta University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Covid19

Treatments: Drug: Daclatasvir; Drug: Sofosbuvir

Study type: Interventional

Funder types: Other

Identifiers

NCT04497649

Tanta sofosbuvir covid

Details and patient eligibility

About

efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Full description

The study aims to assess Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Enrollment: 100 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID 19 positive patients

Exclusion criteria

• COVID-19 patients with critical manifestations.
• Sepsis.
• Acute respiratory distress syndrome (ARDS).
• Decompensated liver disease (Child-Pugh class B or C disease).
• Chronic renal impairment.
• Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ....).
• Ischemic heart disease within the last 6 months.
• Chronic pulmonary disease.
• Malignancy.
• Pregnancy or breastfeeding.
• Hypersensitivity to sofosbuvir or ribavirin.
• Patients with organ transplant.
• Unwilling to participate in our study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups

Sofosbuvir and Daklatasuvir

Experimental group

Description:

Sofosbuvir and Daklatasuvir with standard of care treatment

Treatment:

Drug: Sofosbuvir

Drug: Daclatasvir

Standard of care treatment

No Intervention group

Description:

Standard of care treatment